About Adocia
Adocia is a company based in Lyon (France) founded in 2005. Adocia has raised $26 million across 5 funding rounds from investors including Idinvest Partners, IPF Partners and CDC Enterprises. The company has 77 employees as of December 31, 2024. Adocia offers products and services including BioChaperone® Lispro and Pipeline Products. Adocia operates in a competitive market with competitors including Sana Biotechnology, Semma Therapeutics, Altimmune, Rezolute and Cellino, among others.
- Headquarter Lyon, France
- Employees 77 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Adocia Sa
-
Annual Revenue
$9.68 M (USD)333.49as on Dec 31, 2024
-
Net Profit
-$9.68 M (USD)55.95as on Dec 31, 2024
-
EBITDA
-$10.09 M (USD)43.28as on Dec 31, 2024
-
Total Equity Funding
$26 M (USD)
in 5 rounds
-
Latest Funding Round
$11.73 M (USD), Post-IPO
Dec 18, 2025
-
Investors
Idinvest Partners
& 5 more
-
Employee Count
77
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Adocia
Adocia is a publicly listed company on the EURONEXT with ticker symbol ADOC in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Adocia
Adocia offers a comprehensive portfolio of products and services, including BioChaperone® Lispro and Pipeline Products.
Advanced insulin product for effective diabetes treatment in clinical settings.
Develops formulations for metabolic hormones targeting diabetes and obesity.
People of Adocia
Unlock access to complete
Funding Insights of Adocia
Adocia has successfully raised a total of $26M across 5 strategic funding rounds. The most recent funding activity was a Post-IPO round of $11.73 million completed in December 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Adocia
Adocia has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Idinvest Partners, IPF Partners and CDC Enterprises.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Alternative financing is provided by IPF Partners for healthcare.
|
Locked | Locked | Locked | |
|
Equity investments are provided to low and middle market companies.
|
Locked | Locked | Locked | |
|
Smalt Capital is engaged in capital investment and renewable energy financing.
|
Locked | Locked | Locked |
Investor details for Adocia
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Adocia
Investment portfolio details for Adocia
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Adocia
Detailed financials for Adocia
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Adocia Comparisons
Peer comparison for Adocia
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Adocia
Adocia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Semma Therapeutics, Altimmune, Rezolute and Cellino, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| Locked | Locked | Locked |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| Locked | Locked | Locked |
Therapies for metabolic and orphan diseases are developed by Rezolute.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
Detailed competitors of Adocia
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Adocia
Complete news archive for Adocia
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adocia
Adocia was founded in 2005 and raised its 1st funding round 3 years after it was founded.
Adocia is headquartered in Lyon, France. It is registered at Lyon, Auvergne-rhone-alpes, France.
Adocia is a funded company, having raised a total of $26M across 5 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Adocia is 77.
Annual revenue of Adocia is $9.68M as on Dec 31, 2024.
Adocia was founded in 2005 in Lyon, France, within the biotechnology sector. Therapeutics targeting diabetes and obesity are developed using a proprietary Biochaperone platform, which improves protein effectiveness, safety, and patient administration. The clinical pipeline features a PDGF-BB formulation for diabetic foot ulcers and various insulin options for diabetes management. Operations focus on advancing these protein-based treatments through research and development.
Adocia's top competitors include Imbed Biosciences, Sana Biotechnology and Semma Therapeutics.
Adocia offers BioChaperone® Lispro and Pipeline Products.
Yes, Adocia is publicly traded on EURONEXT under the ticker symbol ADOC.
Adocia has 6 investors. Key investors include Idinvest Partners, IPF Partners, CDC Enterprises, Bioam, and Smalt Capital.
The ticker symbol of Adocia is ADOC on EURONEXT.